Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 6Phase 3 3Phase NA 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 4Withdrawn 1Unknown 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 133Recurrence 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 7Immunoglobulin Light-chain Amyloidosis 7Lymphoma, Non-Hodgkin 6Amyloidosis 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Burkitt Lymphoma 5Paraproteinemias 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Blood Protein Disorders 4Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Lung Neoplasms 3Esophageal Neoplasms 3Corneal Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2

Interventions

Dexamethasone 6Calcium Dobesilate 3Lenalidomide 2Cyclophosphamide 2venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1belantamab mafodotin 1auricularum 1Thalidomide 1Melphalan 1Lisaftoclax 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1GTP Cyclohydrolase 1Drug Evaluation 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Amyloidosis × Dexamethasone × Clear all
NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Mayo Clinic

Phase 1/2 Completed
87 enrolled 13 charts
Plasma cell

Amyloidosis, Multiple Myeloma

NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
108 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

NCT00981708 2021-04-30

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

University of Athens

Phase 1/2 Completed
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Recurrence

NCT02545907 2021-04-15

CATALYST

University College, London

Phase 1/2 Completed
10 enrolled 14 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT00621400 2011-05-10

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

Nantes University Hospital

Phase 1/2 Completed
27 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡